Dr Phil Kearney

‍Dr Phil Kearney has extensive experience in genetics research, including mapping the human Y and X chromosomes. He has led the Haematology Research Laboratory in Sydney, focusing on ribozyme and gene therapy approaches for chronic myeloid leukaemia.

He has held leadership roles in preclinical oncology studies at ActiveBiotech AB in Sweden and Santaris Pharma in Denmark. Dr Kearney later joined Merck Sharp & Dohme (MSD) Australia as the key scout for innovative research and development, and subsequently became the head of the External Licensing group for the Asia Pacific region. This role involved collaborating with biotechnology companies and research institutes to identify drug targets and platform technologies.

After nearly 15 years with MSD, Dr Kearney transitioned to executive roles at Axelia Oncology Pty Ltd and Amaroq Therapeutics.